lower estim reect
hold rate reect view numer structur
challeng could result downsid street organ growth expect
continu challeng cynosur disappoint start panther fusion
launch reinforc view
recent develop prompt anoth cut cynosur forecast
last week announc suspend market distribut
recent launch vitalia handpiec tempsur instrument vitalia
handpiec introduc mid-juli provid heat vagin tissu improv
circul impair sale trajectori product
surpris follow fda letter sent late juli sever compani
suppli laser broadli dene vagin rejuven categori
aesthet market surpris vitalia slate contribut
sale alreadi sequenti lower season cynosur forecast
thu absent sale product infer base cynosur sale guid
better attish year-on-year despit commun progress
salesforc new product launch tempsur envi easi comparison
impact fda letter market claim around mona lisa
touch cynosur sale estim compani total yet
determin class action lawsuit led custom last
week bode well specic plainti lawsuit obstetrician/
gynecolog ob/gyn practic rhode island argu longer use
mona lisa touch instrument follow fda letter fear subject
patient harm liabil
taken harder look entir cynosur forecast
initi reduc last month expect organ sale growth
growth new forecast reect growth lag
peer inde allergan continu express strength recent
acquisit cynosur competitor zeltiq instrument placement vs pre-
acquisit sale march quarter competitor also
continu report strength specic highlight almost year-on-
year growth trusculpt product june quarter
price aug usd
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
cynosur motiv downward revis forward estim
busi compris sale forecast
meanwhil earli disappoint panther fusion molecular
alway consid molecular diagnost busi
sale compani crown jewel though oncom
underappreci deceler busi key compon
januari downgrad last week downward guidanc revis
partner stratec sgsg de cite part slower expect ramp
recent launch panther fusion instrument suggest path reacceler
easi one said major investor reacceler thesi
molecular rest viral load test rather panther fusion
price target
forecast ratio
period end expens share share sale growth ex acquir intang cash flowoper cash cash sale present conform adjust ep report compani exclud blood base onward consist compani present
period end asset cash receiv incom tax held expens defer tax current plant intang asset liabil current portion long term current current debt net incom tax long-term liabil stockhold august
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur
primari subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/
research/disclosures/companysearch asid within report import risk conict disclosur also found http //research db com/research/topics/equ
investor strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
